
    
      This will be a placebo-controlled, randomized, double-blind, parallel-arm trial. The study
      will consist of one screening (visit 1a, week 0), one baseline visit (visit 1b, week 0), and
      three treatment visits (visits 2, 3, and 4; weeks 4, 8, and 16).
    
  